搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
10 小时
Imfinzi在膀胱癌试验中显示前景,寻求FDA批准
华盛顿 - ...
腾讯网
19 小时
死亡风险降低27%!这类难治癌症终迎首款免疫治疗药物……
欢迎关注凯莱英药闻2024 年 12 月 5 日,阿斯利康宣布,美国FDA批准Imfinzi (durvalumab,度伐利尤单抗) 的新适应症上市申请,用于治疗在同时进行铂类化疗和放疗(cCRT)后病情未进展的局限期小细胞肺癌 (LS-SCLC) ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Manslaughter charge dropped
US adds 227,000 jobs
Romanian election annulled
Several prisons to be closed
Syrian rebels advance
Recalls 300K+ Ram trucks
Havana syndrome report
Trump shows public support
AI bias meter coming
'Patriot of the Year' award
Biden considers pardons
Promotes trade w/ Mexico
Iran: Space launch successful
Scott tapped to lead CBP
Family awarded $310 million
NBA returning to China
Judge rejects plea deal
Taking extended leave
Appeals court upholds ban
Hit six months in space
Messi wins MLS MVP award
‘One Life to Live’ star dies
Wild bird lays egg at 74
Federal fraud charges arrest
Oven gloves recalled
Massive fire in Baltimore
Blackhawks fire coach
Meet with lawmakers
Moon missions delayed
Joins X Games as CEO
Ethics report release blocked
Pledges hit $100 billion
White Sox legend dies
Sacks to lead AI, crypto
反馈